Skip to content

Arrowhead Research ARWR Accrued Progress Collections and Price Adjustments

Accrued Progress Collections and Price Adjustments at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Moderna logo
ModernaMRNA
Exelixis logo
ExelixisEXEL

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's accrued progress collections and price adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's accrued progress collections and price adjustments?
Arrowhead Research (ARWR) reported accrued progress collections and price adjustments of $48.62M in Q1 2026.
What is the long-term trend for Arrowhead Research's accrued progress collections and price adjustments?
Over 3 years (2021 to 2025), Arrowhead Research's accrued progress collections and price adjustments has grown at a -100.0% compound annual growth rate (CAGR), from $131.5M to $0.